Storys zum Thema Therapie

Sysmex Europe SE

2

Fundació Puigvert validates a new tool capable of selecting the most suitable antibiotic for uncomplicated urinary tract infections within 45 minutes.

STADA Arzneimittel AG

Press release: STADA welcomes CHMP positive opinion on extending indication for Kinpeygo

STADA welcomes CHMP positive opinion on extending indication for Kinpeygo - The CHMP adopted a positive opinion recommending a change to the terms of the marketing authorization of Kinpeygo for the treatment of adults with primary immunoglobulin A, now covering patients with a UPCR of ≥0.8 g/g - ...

STADA Arzneimittel AG

Press release: Bio-Thera and STADA Reach Exclusive Agreement for BAT2506, a Proposed Golimumab Biosimilar, in the EU and UK

Bio-Thera and STADA Reach Exclusive Agreement for BAT2506, a Proposed Golimumab Biosimilar, in the EU and UK - Bio-Thera and STADA have reached an exclusive commercialization and license agreement for BAT2506, a biosimilar candidate to Simponi® ...

STADA Arzneimittel AG

2

Press release : People with Parkinson’s experience variations in effects of oral medicines, but lack advice, international survey reveals

STADA Arzneimittel AG

Press release: STADA and Xbrane secure EU approval for Ximluci® (ranibizumab) biosimilar referencing Lucentis®

STADA and Xbrane secure EU approval for Ximluci® (ranibizumab) biosimilar referencing Lucentis® - European Commission grants pan-EU marketing authorization for Ximluci® biosimilar referencing Lucentis® (ranibizumab) - Paves way for European ...

Fördergesellschaft IZB mbH

2

Lindis Biotech develops immunotherapy against bladder cancer

Fördergesellschaft IZB mbH

3

World Cancer Day: Start-ups at the IZB develop innovative cancer drugs and diagnostic tools

Fördergesellschaft IZB mbH

The development of a combination drug for immunotherapy and trends of the VC and pharmaceutical branch were introduced at the IZB